2024-511964-95-00
Not yet recruiting
Phase 2
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trial
Azienda Ospedale-Universita Padova3 sites in 1 country110 target enrollmentStarted: June 27, 2024Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Azienda Ospedale-Universita Padova
- Enrollment
- 110
- Locations
- 3
- Primary Endpoint
- Incidence of global adverse events and incidence of serious adverse events.
Overview
Brief Summary
The primary objective of the study will be to evaluate the safety of dapagliflozin versus standard medical therapy in patients with decompensated liver cirrhosis.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 18 and 85 years
- •Diagnosis of liver cirrhosis, documented on the basis of histological examination and/or clinical and/or instrumental examinations (ultrasonography, CT scan or liver elastography > 15 kPa)
- •Liver cirrhosis decompensation (overt hepatic encephalopathy, clinically significant ascites, hemorrhage from esophageal varices) developed within the past 12 months
Exclusion Criteria
- •Established hypersensitivity to Dapaglifozin
- •Patient who is a carrier of TIPS
- •Active therapy for HCV eradication with Direct Antiviral Agents or terminated < 6 months before
- •Therapy for HBV suppression with nucleoside/nucleotide analogs started < 6 months before
- •Active alcohol consumption greater than 21 weekly alcohol units
- •Presence of at least one episode of acute kidney injury (AKI) in the 4 weeks prior to enrollment
- •Presence of two or more episodes of urinary tract infection in the 12 months prior to enrollment
- •Presence of >2 episodes of "overt" hepatic encephalopathy in the 12 months prior to enrollment
- •Body mass index (BMI) < 20 kg/m^2
- •History of prior solid organ transplantation
Outcomes
Primary Outcomes
Incidence of global adverse events and incidence of serious adverse events.
Incidence of global adverse events and incidence of serious adverse events.
Secondary Outcomes
- Composite endpoints of further decompensation of cirrhosis (occurrence of variceal bleeding, hepatic encephalopathy, new-onset ascites or recurrent ascites, hepatorenal syndrome, spontaneous bacterial peritonitis) and death assessed at day 28 (± 7), 56 (± 7), 84 (± 7), 112 (± 7), 140 (± 7), and 168 (± 7)
- Incidence of new onset ascites
- Incidence of recurrent ascites
- Incidence of hepatic encephalopathy
- Incidence of variceal bleeding
- Incidence of hepatorenal syndrome
- Incdencde of spontaneous bacterial peritonitis
- Change from baseline in MELD score, MELD-Na score, and Child-Pugh score at day 28 (± 7), 56 (± 7), 84 (± 7), 112 (± 7), 140 (± 7), and 168 (± 7)
- Change in EQ-5D quality of life questionnaire score at day 84 (± 7) and 168 (± 7)
- Change in Liver Frailty index at day 28 (± 7), 56 (± 7), 84 (± 7), 112 (± 7), 140 (± 7) and 168 (± 7)
- Change from baseline in creatinine and estimated glomerular filtrate values at day 28 (± 7), 56 (± 7), 84 (± 7), 112 (± 7), 140 (± 7) and 168 (± 7)
- Incidence of acute over chronic liver failure
- Change from baseline in 24-hour sodiuria at day 28 (± 7), day 84 (± 7) and 168 (± 7).
- Change from baseline in body weight at day 28 (± 7), 56 (± 7), 84 (± 7), 112 (± 7), 140 (± 7) and 168 (± 7).
- Change from baseline in proinflammatory cytokines (IL1beta, IL6, IL8, IL10, TNF-alpha, IL1ra) at day 84 (± 7) and 168 (± 7).
- Change from baseline in markers of circulatory dysfunction (renin, aldosterone, copeptin) at day 84 (± 7) and 168 (± 7).
- Change from baseline in markers of oxidative stress (oxidized albumin isoforms HNA1 and HNA2, thiobarbituric acid reactive substance assay) at day 84 (± 7) and 168 (± 7).
- Change from baseline in markers of endothelial dysfunction (von Willebrand factor) at day 84 (± 7) and 168 (± 7).
- Change from baseline in markers of liver fibrosis (PRO-C3, PRO-C6) at day 84 (± 7) and 168 (± 7),
- Change from baseline in biomarkers of bacterial translocation (lipopolysaccharide binding protein, LBP) at day 84 (± 7) and 168 (± 7)
- Change from baseline of "DAMPs" biomarkers (mitochondrial DNA, HMGB1) at day 84 (± 7) and 168 (± 7)
- Change from baseline in metabolites measured by untargeted metabolomics at day 84 (± 7) and 168 (± 7)
Investigators
Salvatore Silvio Piano
Scientific
Azienda Ospedale-Universita Padova
Study Sites (3)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trialCTIS2024-511964-95-00Azienda Ospedale-Universita Padova110
Completed
Phase 1
Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.2024-515238-34-00Laboratorios Alter S.A.30
Recruiting
Phase 3
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure2023-506460-14-00Astrazeneca AB1,310
Not yet recruiting
Phase 4
Early use of dapagliflozin in patients with acute myocardial infarction and reduced ejection fraction: the randomized ARMYDA-9 Dapagliflozin trial2025-521481-10-00Azienda Ospedaliero-Universitaria Maggiore Della Carita140
Not yet recruiting
Phase 3
Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure2024-517977-26-00Friedrich-Schiller-Universitaet Jena556